People · Operator
Named in public records as an officer, director or promoter · active 2021–2023 · Biotechnology, Biotech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bonum Therapeutics, Inc. | — | Biotechnology | Series C | $46.2M | $746.8M | 2021 |
| Good Therapeutics, Inc. | — | Biotechnology | Series B | $31.1M | $188.9M | 2021 |
| Abacus Bioscience Inc. | — | Biotech | Series A | $4.4M | $46.6M | 2023 |
Diane Hollenbaugh at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Diane Hollenbaugh on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| NICHOLAS WALROD | 2 | 8 |
| John McKearn | 2 | 6 |
| Mitchell Mutz | 2 | 5 |
| John Mulligan | 2 | 3 |
| Karl Handelsman | 2 | 3 |
| Neela Patel | 2 | 2 |
| Monique Schiersing | 2 | 2 |
| Jonathan Drachman | 1 | 2 |
| Samuel Bjork | 1 | 2 |
| Will Canestero | 1 | 1 |
| Che-Leung Law | 1 | 1 |
| Alan Wahl | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.